Erin Ringley
Family · Mount Airy, NCNPI 1245916725
Payments from drug & device makers
Across 94 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$232
- Otsuka America Pharmaceutical, Inc.$172
- Bayer$170
- AstraZeneca$165
- Novo Nordisk$126
- Axsome Therapeutics, Inc.$116
- plus $717 from 17 others
What the payments were for
- Food & beverage$1,699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $232 |
| Otsuka America Pharmaceutical, Inc. | 8 | $172 |
| Bayer | 10 | $170 |
| AstraZeneca | 9 | $165 |
| Novo Nordisk | 8 | $126 |
| Axsome Therapeutics, Inc. | 4 | $116 |
| Collegium Pharmaceutical, Inc. | 5 | $102 |
| Shield Therapeutics Inc | 5 | $82 |
| GSK | 4 | $72 |
| Lilly USA, LLC | 4 | $70 |
| Exact Sciences | 3 | $53 |
| Indivior Inc. | 2 | $48 |
| Forte Bio-pharma LLC | 2 | $45 |
| Pfizer | 2 | $45 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Virtus Pharmaceuticals LLC | 1 | $26 |
| Vertex | 1 | $25 |
| Abbott | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Gilead | 1 | $22 |
| Amgen | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
How this compares
$1,699 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 80 | $91,386 |
| Xtampza ErOxycodone Myristate | 122 | $56,557 |
| OzempicSemaglutide | 37 | $44,133 |
| UbrelvyUbrogepant | 27 | $39,991 |
| BelbucaBuprenorphine Hcl | 33 | $31,263 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 628 | $27,648 |
| ZtlidoLidocaine | 25 | $26,722 |
| LinzessLinaclotide | 32 | $25,432 |
| RybelsusSemaglutide | 17 | $21,815 |
| Oxycodone Hcl | 855 | $17,801 |
| FarxigaDapagliflozin Propanediol | 15 | $15,144 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 314 | $11,818 |
| Lidocaine | 66 | $11,368 |
| OxycontinOxycodone Hcl | 24 | $10,982 |
| Hysingla ErHydrocodone Bitartrate | 20 | $9,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $70 | $91,38680 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $102 | $87,820155 claims |
| Novo NordiskOzempic, Rybelsus | $126 | $65,94854 claims |
| AbbVieUbrelvy, Linzess | $232 | $65,42359 claims |
| PfizerEliquis, Lyrica | $45 | $16,04822 claims |
| AstraZenecaFarxiga | $165 | $15,14415 claims |
| BayerKerendia | $170 | $9,43712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Mount Airy
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.